Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENXBIO Inc. Director's Dealing 2018

Nov 5, 2018

32827_dirs_2018-11-05_d71b1bff-a2ab-4404-b3b9-415185f3ffa2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENXBIO Inc. (RGNX)
CIK: 0001590877
Period of Report: 2018-11-01

Reporting Person: Vasista Vittal (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-11-01 Common Stock M 9959.00 $3.76 Acquired 147242.00 Direct
2018-11-01 Common Stock M 9718.00 $13.09 Acquired 156960.00 Direct
2018-11-01 Common Stock S 19677.00 $70.04 Disposed 137283.00 Direct
2018-11-02 Common Stock M 32908.00 $13.09 Acquired 170191.00 Direct
2018-11-02 Common Stock M 20833.00 $19.50 Acquired 191024.00 Direct
2018-11-02 Common Stock S 53741.00 $70.26 Disposed 137283.00 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-11-01 Employee Stock Option (Right to Buy) $3.76 M 9959.00 Disposed 2025-05-18 Common Stock (9959.00) Direct
2018-11-01 Employee Stock Option (Right to Buy) $13.09 M 9718.00 Disposed 2026-01-27 Common Stock (9718.00) Direct
2018-11-02 Employee Stock Option (Right to Buy) $13.09 M 32908.00 Disposed 2026-01-27 Common Stock (32908.00) Direct
2018-11-02 Employee Stock Option (Right to Buy) $19.50 M 20833.00 Disposed 2027-01-03 Common Stock (20833.00) Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.

F5: The previously granted option, representing a right to purchase a total of 75,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.

F6: The previously granted option, representing a right to purchase a total of 50,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.